Skip to main content

Monte Rosa Therapeutics banks 96 million US dollars

| News

Monte Rosa Therapeutics banks 96 million US dollars


The Basel-based biotechnology firm Monte Rosa Therapeutics has raised a total of 96 million US dollars after closing a successful Series B financing round. Using this fresh injection of capital, the company intends to drive forward the development of its molecule degradation platform that aims to eradicate proteins regarded either as difficult to medically treat or untreatable that occur in cases of cancer, for example.

Monte Rosa Therapeutics, a biotechnology company based in Basel, has raised to a total of 96 million US dollars as part of a Series B financing round. “The company is now poised to bring forward multiple drug candidates for some of the most difficult to treat cancers and other diseases”, comments Alexander Mayweg, Chairman of the Board of Directors, in a press release.

This financing round was led by Aisling Capital, although both Versant Ventures and the existing investor New Enterprise Associates were also involved in the process. In addition, Monte Rosa can call upon a further seven new investors. “We are pleased to have the support of this strong group of investors”, states Markus Warmuth, CEO of Monte Rosa, in the press release. As a result, the company is “now well positioned to broadly develop our integrated drug discovery platform and advance multiple new therapies toward clinical development”, Warmuth adds.

With the help of the platform developed by Monte Rosa, it should now be possible to design and develop small molecule degraders even more rationally. These are designed to complement the body’s innate ability to degrade proteins. With this approach, Monte Rosa Therapeutics is aiming to eradicate proteins that cause diseases regarded either as difficult to medically treat or which are untreatable, including those present in cancers. “Many approved drugs have been developed to inhibit a protein’s function. Monte Rosa’s goal is to eliminate the protein altogether”, explains Andrew Schiff from Aisling Capital. In connection with this financing round, Schiff is set to join the Board of Directors at Monte Rosa, as will Chandra P. Leo of HBM Partners.

Monte Rosa Therapeutics has offices in the centre of Basel and labs in the Technologiepark Basel. Versant Ventures also has offices in Basel.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.